Cellerix, a product-focused biopharmaceutical company which develops innovative medicines based on cell therapy, today announced the successful first closing of its financing round, raising €27 million. Participants in this capital increase included current shareholders and a select group of new investors. Cellerix completed another financing round for €27.2 million in September 2007.
This round was led by the leading life science venture capital funds YSIOS Capital Partners, LSP (Life Science Partners) and Ventech. Grupo Genetrix also played a key role in the deal, and two of Cellerix’ current investors (Roche Venture Fund and Novartis Venture Fund) have significantly increased their stake. Furthermore, A&G and Cellerix’ management team have also subscribed to the capital increase. Florent Gros (representing Novartis) and a second representative from Genetrix, still to be designated will join Cellerix board of directors.
The new Cellerix shareholders include Bankinter S.A., Capital Riesgo Madrid and JV Risk Technologies S.L.
Joël Jean-Mairet, Cellerix’s Chairman has commented “The size of this round and the quality of the participants show investor’s confidence in the potential of Cellerix and its management team. Cellerix is becoming a world reference in the emerging cell therapy area as it moves towards the market launch of its first product backed by a very interesting pipeline”.
The funds raised by Cellerix in this financing round will be used for funding the completion of the clinical development of its lead product – Ontaril® – and preparation for its market launch in H2 2011. The proceeds of the round will also be used for funding the development additional products in the pipeline, including allogenic programs for the treatment of the autoimmune diseases.
Eduardo Bravo, Cellerix’ CEO added “This capital injection will allow us to continue with the development of all of our programs following the planned schedule, as well as enabling us to defend and increase Cellerix’ leading position in the field, helping us to become the first company to commercialise a cell therapy medicine in Europe”.
Notes to the editor
Cellerix is a biopharmaceutical company developing innovative medicines based on cell therapy. The company has three products undergoing clinical trials: Ontaril® (Cx401) for the treatment of perianal fistulas, currently in Phase III, Cx501 for skin regeneration, currently in Phase II and Cx601 for the treatment of perianal fistulas, in phase II. Ontaril®, Cx501 and Cx601 have been designated orphan status by the European Medicines Agency (EMEA).
For further information about Cellerix, please visit www.cellerix.com
Ysios Capital Partners
Ysios Capital Partners is a new Spanish venture capital firm that launched its first fund of EUR 70 million in 2008 and invests in innovative life science companies. Ysios has offices in Barcelona and San Sebastian (Spain), making investments globally with a special focus on the Spanish market. Ysios has a team of nine professionals with diverse backgrounds in life sciences and healthcare, venture capital, managing start-ups, and corporate finance.
More information is available at www.ysioscapital.com
LSP – Life Sciences Partners-
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. More information is available at www.lspvc.com.
Ventech is a venture capital firm with more than €360 million ($540 million) under management. Created 10 years ago Ventech invests in innovative companies in both the Information Technology and Life Science sectors. Originally based in Paris, Ventech is now also present in China. In the Life Science sector, the objective is to invest primarily in Europe and the US with a specific focus towards drug discovery, diagnostics and medical device technologies.
More information is available at www.ventechvc.com.
Roche Venture Fund
The Roche Venture Fund makes investments in early stage biotech and diagnostics companies to support innovative technologies and medicines. Based in Basel, Switzerland, the Roche Venture Fund manages a portfolio of over 30 companies in 10 countries.
More information is available at www.venturefund.roche.com
Novartis Venture Funds
The Novartis Venture Funds, established in 1996 currently manages over $700 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. Our primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems. The Funds invest for financial objectives at all stages, but prefers to invest in the early-stages of company development. With eight investment professionals located in Basel, Switzerland and Cambridge, MA the team has extensive experience in pharmaceutical R&D and venture capital.
More information is available at http://www.venturefund.novartis.com
Genetrix is the largest private Group of biotech companies in Spain and invests in, starts up, and develops innovative life sciences companies with high growth potential. Genetrix, incorporated in 2001, stands out for its broad experience in building viable biotechnology businesses and converting basic research into clinical results and commercial applications. The Group’s financial resources have exceeded €50 million in the last five years, and the investments carried out by Genetrix in the Group companies during the last 5 years exceeded €20 million.
More information is available at www.genetrix.es
Bankinter, the sixth Spanish Bank in terms of size, is a reference in the financial market for its high technological development, a quality of service superior to the average of the sector and its clear commitment to innovation and the use of alternative channels in its relationship with customers. Bankinter was a pioneer in introducing distance banking systems to complement the traditional branches network, such as phone banking, Internet banking, and more recently mobile banking. This has lead Bankinter to offer a great diversity of possibilities for relationships with customers and products commercialization, with a perfectly integrated multichannel strategy. Bankinter is considered as one the the most innovative companies in the world: products and channels innovation, as well as an innovative way to do and project things.Innovate and do things differently and before anybody else is for Bankinter one of the few sustainable competitive advantages in the long term.
More information is available at www.bankinter.com